Families seeking treatment to deal with the issues presented by children with autism – in communication, speech, emotion and bonding - can gain hope from results of a new study encompassing the use of MedDEV’s Respen-A(TM) (http://www.respen-a.com), a topical disc containing a proprietary homeopathic of ethanol/glycerin and 12C dilution of reserpine, a very old blood pressure medication.

Reserpine is FDA approved for use as an antihypertensive and for the treatment of agitated psychotic states such as associated with schizophrenia.

Under the care of Dr. Anju Usman, a specialist in autism spectrum disorders (ASD), a group of nine patients with an average of 13.5 years of age were prescribed Respen-A and evaluated after a three-month period. Eight of the nine patients at the beginning of the study had been evaluated to have moderate to severe autism and one patient had mild to moderate autism.

Study results showed that improvements after three months according to their baseline total Childhood Autism Rating Scale (CARS) score were significant, while total ATEC scores showed highly significant improvements.

"Using nutrigenomics, MAO-A SNPs, and cholesterol levels to individualize treatment, the homeopathic Respen-A patches provided a statistically significant improvement in my patients," stated Usman. "These results were unexpected because of the small study size, the older age of the patients, and the chronic nature of their issues that improved in just three months."

Evaluation tools used to assess the medication's effectiveness are industry standard ATEC - a parent-rated measure - from the Autism Research Institute and the Childhood Autism Rating Scale (CARS) - the health care professional assessment.

Because of the strong effect size of the Respen-A, the power of the study was well above .80, which is the acceptable power for scientific studies. The fact that Dr. Usman's study only included nine patients, the Respen-A homeopathic treatment would need to have a very strong effect size to show a statistical significant effect.

Despite the small number of patients analyzed in the study, Respen-A showed a highly statistical significant effect with a p value of 0.001. The p value measures the probability of getting results by chance alone; p value of 0.05 or less is considered statistically significant, meaning there are only 5 in 100 chances that the results were in error. The improvement in the total ATEC scores with patients applying the Respen-A topical disc for three months achieved a p value of 0.001, meaning there are only 1 in 1,000 chances that the improvements seen with the Respen-A disc were simply by chance alone.

MEDIA: To arrange for an interview and photos, contact [NAME] at [PHONE] or by email [EMAIL].